Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials

Fig. 2

Mean change from baseline in the MAMD among participants with (a) EMa and (b) CMb. CM, chronic migraine; EM, episodic migraine; MAMD, monthly average migraine days; SE, standard error. aFor participants with EM, response was defined as a reduction of ≥2 MAMD. bFor participants with CM, response was defined as a reduction of ≥4 MAMD

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us